Adaptimmune

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Adaptimmune sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials none currently recruiting 4 completed early-phase tilt top decile by trial count

Adaptimmune: 13 sponsored US clinical trials, none currently recruiting.

Adaptimmune sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is AFP Expressing Tumors, with 1 trials.

Top-decile sponsor footprint

Adaptimmune ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

4 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (36.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

13 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 1

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT03132922
ACTIVE NOT RECRUITING Phase 1

AFPᶜ³³²T in Advanced HCC

NCT03132792
TERMINATED Phase 2

ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

NCT04752358
TERMINATED Phase 1

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

NCT06048705
TERMINATED Phase 1

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

NCT05943990
TERMINATED Phase 1

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

NCT04526509
TERMINATED

Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

NCT03391791
COMPLETED Phase 1

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

NCT02989064
COMPLETED

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

NCT02636855
COMPLETED Phase 1

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

NCT02592577
TERMINATED Phase 1

CT Antigen TCR-Engineered T Cells for Myeloma

NCT01892293
COMPLETED Phase 1

CT Antigen TCR-redirected T Cells for Ovarian Cancer.

NCT01567891
TERMINATED Phase 1

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

NCT01350401

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 1

Therapeutic Areas

AFP Expressing Tumors 1
Hepatocellular Cancer 1
Gastroesophageal Junction 1
Gastric Cancer 1
Urinary Bladder Cancer 1
Myxoid/Round Cell Liposarcoma 1
Synovial Sarcoma 1
Esophageal Cancer 1
Melanoma 1
Non-Small Cell Lung Cancer 1

How the Adaptimmune early-phase archive is shaped

13 indexed studies, none listed as recruiting (0% open); 4 completed (31%).

Phase mix: 0 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: AFP Expressing Tumors (1 trial), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Adaptimmune: archived-pipeline peers nationwide

Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Adaptimmune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%2%4%6%8%10% Total trials Recruiting share AdaptimmuneAgennixAkili Interactive LabsAlumisAndrei Iagaru10xBio22nd Century Group23andMe3-C Institute for Social Development
Adaptimmune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Adaptimmune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Adaptimmune page

13 registered trials is a research-attention snapshot, not an endorsement of Adaptimmune or any single study.

  • None of Adaptimmune's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • AFP Expressing Tumors is the condition Adaptimmune studies most, compare against other sponsors active in the same condition before evaluating a specific study. See AFP Expressing Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Adaptimmune pipeline card: 13 registered trials from official public datasets.Report a data error.